Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial
Biomolecules 9:232
Percent change was calculated by subtracting the baseline weight for a person from a given measurement and dividing by the baseline weight
Eligibility: Both medications are approved for adults with a BMI of 30 or above, or 27 or above if another weight-related condition (such as type 2 diabetes, hypertension, or sleep apnoea) is present
ECC5004 further strengthens our existing pipeline addressing both incretin and non-incretin pathways, including our GLP-1/glucagon dual agonist [AZD9550] and long-acting amylin analogue [AZD6234]." Under the terms of the agreement, Eccogene will receive an initial upfront payment of $185 million
Always follow the disposal advice in the patient information leaflet that comes with your treatment